Expression level of the growth factor progranulin is related with development of systemic lupus erythematosus

Diagnostic Pathology

Xingfu Li¹  Weiwei Liu²  Ning Yang²  Qiang Shu²  Huaxiang Liu²  Feng Ding²  Lijun Song²  Feng Qiu² 

[1] Department of Rheumatology, Qilu Hospital, Shandong University, No. 107, Wenhua Xi Road, Jinan 250012, P. R. China;Department of Rheumatology, Qilu Hospital, Shandong University, Jinan 250012, P. R. China

关键词: IL-6;    Glucocorticoid;    Progranulin;    Systemic lupus erythematosus;   

Others  :  806866
DOI  :  10.1186/1746-1596-8-88

 received in 2013-01-30, accepted in 2013-05-11,  发布年份 2013

【 摘 要 】

Background

This study is to investigate the expression of progranulin (PGRN) in systemic lupus erythematosus (SLE) patients and the effect of glucocorticoid (GC) treatment on its expression.

Methods

Thirty newly diagnosed severe SLE patients and 30 healthy subjects were enrolled in this study. The serum levels of PGRN and the inflammatory factors of SLE were detected by ELISA and the mRNA expression of these proteins were detected by real-time PCR.

Results

The serum levels of PGRN, IL-6, PR3, TNFR, TNF-α and anti-dsDNA antibody in SLE patients were increased significantly compared with healthy controls (P < 0.05). The relative expression of PGRN mRNA was increased by 4.88-fold in pre-treatment SLE patients compared with controls (P < 0.05). After prednisone treatment, the serum levels of PGRN decreased significantly, and the relative expression of PGRN mRNA was decreased by 1.34-fold compared with the untreated controls (P < 0.01). Moreover, Serum concentration of PGRN was correlated with serum levels of IL-6, TNF-α, TNFR and anti-dsDNA antibody in both pre-treatment and post-treatment SLE patients.

Conclusions

PGRN is up-regulated in the SLE patients and is correlated with pro-inflammatory cytokines and anti-dsDNA antibody. Glucocorticoids can down-regulate the expression of PGRN in SLE patients.

Virtual slides

http://www.diagnosticpathology.diagnomx.eu/vs/1562484036905973 webcite

【 授权许可】

   
2013 Qiu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Herrmann M, Voll RE, Kalden JR: Etiopathogenesis of systemic lupus erythematosus. Immunol Today 2000, 21:424-426.
• [2]Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, Liu GY, Syed NM, Lai Y, Lin EA, Kong L, Su J, Yin F, Ding AH, Zanin-Zhorov A, Dustin ML, Tao J, Craft J, Yin Z, Feng JQ, Abramson SB, Yu XP, Liu CJ: The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 2011, 332:478-484.
• [3]Kleiman A, Tuckermann JP: Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol Cell Endocrinol 2007, 275:98-108.
• [4]Stahn C, Buttgereit F: Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008, 4:525-533.
• [5]Bossù P, Neumann D, Del Giudice E, Ciaramella A, Gloaguen I, Fantuzzi G, Dinarello CA, Di Carlo E, Musiani P, Meroni PL, Caselli G, Ruggiero P, Boraschi D: IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci USA 2003, 100:14181-14186.
• [6]Hrabal R, Chen Z, James S, Bennett HP, Ni F: The hairpin stack fold, a novel protein architecture for a new family of protein growth factors. Nat Struct Biol 1996, 3:747-752.
• [7]Bateman A, Bennett HP: The granulin gene family: from cancer to dementia. Bioessays 2009, 31:1245-1254.
• [8]Feng JQ, Guo FJ, Jiang BC, Zhang Y, Frenkel S, Wang DW, Tang W, Xie Y, Liu CJ: Granulin epithelin precursor: a bone morphogenic protein 2-inducible growth factor that activates Erk1/2 signaling and JunB transcription factor in chondrogenesis. FASEB J 2010, 24:1879-1892.
• [9]Daniel R, He Z, Carmichael KP, Halper J, Bateman A: Cellular localization of gene expression for progranulin. J Histochem Cytochem 2000, 48:999-1009.
• [10]He Z, Ong CH, Halper J, Bateman A: Progranulin is a mediator of the wound response. Nat Med 2003, 9:225-229.
• [11]Kessenbrock K, Fröhlich L, Sixt M, Lämmermann T, Pfister H, Bateman A, Belaaouaj A, Ring J, Ollert M, Fässler R, Jenne DE: Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J Clin Invest 2008, 118:2438-2447.
• [12]Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, Lacomis L, Erdjument-Bromage H, Tempst P, Wright CD, Ding A: Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002, 111:867-878.
• [13]Guo F, Lai Y, Tian Q, Lin EA, Kong L, Liu C: Granulin-epithelin precursor binds directly to ADAMTS-7 and ADAMTS-12 and inhibits their degradation of cartilage oligomeric matrix protein. Arthritis Rheum 2010, 62:2023-2036.
• [14]Mageed RA, Isenberg DA: Tumour necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production. Lupus 2002, 11:850-855.
• [15]Hindawi Publishing Corporation: J Biomed Biotechnol. 2011:14. Article ID 432595
• [16]Lotz M, Jirik F, Kabouridis P, Tsoukas C, Hirano T, Kishimoto T, Carson DA: B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med 1988, 167:1253-1258.
• [17]Naka T, Nishimoto N, Kishimoto T: The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002, 4:S233-S242. BioMed Central Full Text
• [18]Suzuki H, Yasukawa K, Saito T, Narazaki M, Hasegawa A, Taga T, Kishimoto T: Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur J Immunol 1993, 23:1078-1082.
• [19]Tang B, Matsuda T, Akira S, Nagata N, Ikehara S, Hirano T, Kishimoto T: Age-associated increase in interleukin 6 in MRL/lpr mice. Int Immunol 1991, 3:273-278.
• [20]Tackey E, Lipsky PE, Illei GG: Illei, Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004, 13:339-343.
• [21]Gröndal G, Gunnarsson I, Rönnelid J, Rogberg S, Klareskog L, Lundberg I: Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000, 18:565-570.
• [22]Eilertsen GØ, Nikolaisen C, Becker-Merok A, Nossent JC: Nossent, Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus. Lupus 2011, 20:607-613.
• [23]Mihara M, Nishimoto N, Ohsugi Y: The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther 2005, 5:683-690.
• [24]Buttgereit F, Burmester GR, Lipworth BJ: Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 2005, 365:801-803.
• [25]Schäcke H, Berger M, Rehwinkel H, Asadullah K: Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007, 275:109-117.
• [26]Kanodia KV, Vanikar AV, Goplani KR, Gupta SB, Trivedi HL: Sickle cell nephropathy with diffuse proliferative lupus nephritis: a case report. Diagn Pathol 2008, 3:9. BioMed Central Full Text
• [27]Uehara A, Sato T, Iwashiro A, Yokota S: PR3-ANCA in Wegener’s granulomatosis prime human mononuclear cells for enhanced activation via TLRs and NOD1/2. Diagn Pathol 2009, 4:23. BioMed Central Full Text